Rheonix, Inc. Announces New SeptiCARD Data Demonstrating Rapid Septicemia Diagnosis
Published: Jul 28, 2011
ITHACA, N.Y.--(BUSINESS WIRE)--Rheonix, Inc. today announced positive results in a new application of its powerful, automated, molecular diagnostic platform, termed SeptiCARD, for the detection of septicemia, the presence of bacteria in the blood often associated with severe infection. Results were presented in a poster session at the American Association for Clinical Chemistry (AACC) Annual Meeting held in Atlanta, Ga., July 24-28, 2011. These data continue to support the Rheonix CARD® system’s utility across a range of molecular diagnostic applications.